You'll discover how these supplements work, what realistic results to expect, and whether combining them could amplify your skincare routine
"Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist." JCI Insight , 5(17), e140532
The V1 and V2 platforms were variants of the Illumina HumanHap550 BeadChip and contained a total of about 560,000 SNPs, including about 25,000 custom SNPs selected by 23andMe
E.DowdallS
Consider these research findings: Biofilm formation: Bacterial biofilms can form in chronic nummular lesions, contributing to treatment resistance [3] Altered drug penetration: The thick, scaly (hyperkeratotic) nature of chronic lesions can reduce the absorption of topical medications [13] Neurogenic inflammation: The density of nerve fibers containing Substance P, a neuropeptide involved in inflammation and itching, is significantly increased in nummular eczema lesions [14] Most frustrating is the rebound phenomenon that can occur after discontinuing topical steroids, which can lead to a dependency cycle [15]
Here's how tesamorelin vs sermorelin and other GHRH peptides compare: GHRH Peptide Comparison Table Property Tesamorelin Sermorelin CJC-1295 (No DAC) CJC-1295 DAC FDA Status FDA Approved (Egrifta) Previously approved, now discontinued Not approved Not approved Amino Acids 44 (modified GHRH) 29 (GHRH 1-29) 29 + modifications 29 + Drug Affinity Complex Half-Life ~26-38 minutes ~10-20 minutes ~30 minutes ~6-8 days Mechanism GHRH receptor agonist GHRH receptor agonist GHRH receptor agonist GHRH receptor agonist (extended) Clinical Trial Data Extensive (Phase 3 completed) Limited (older studies) Limited (Phase 1/2) Limited Primary Research Use Lipodystrophy, NAFLD, body composition GH deficiency research GH axis research Extended GH release research Key Differentiators Tesamorelin's advantages: Only GHRH analog with current FDA approval Extensive Phase 3 clinical trial data Documented efficacy for visceral fat reduction Well-characterized safety profile from prescription use Sermorelin note: Previously FDA-approved (1997) for pediatric growth hormone deficiency but discontinued by manufacturers no longer available as a prescription product in the US
